
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About
CASI Pharmaceuticals Inc (CASI)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/03/2025: CASI (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -1.56% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 86.58M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 54182 | Beta 0.65 | 52 Weeks Range 2.05 - 7.67 | Updated Date 02/14/2025 |
52 Weeks Range 2.05 - 7.67 | Updated Date 02/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.03 |
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -117.68% | Operating Margin (TTM) -240.11% |
Management Effectiveness
Return on Assets (TTM) -26.6% | Return on Equity (TTM) -85.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 38434784 | Price to Sales(TTM) 1.76 |
Enterprise Value 38434784 | Price to Sales(TTM) 1.76 | ||
Enterprise Value to Revenue 1.74 | Enterprise Value to EBITDA 0.07 | Shares Outstanding 15461100 | Shares Floating 5948099 |
Shares Outstanding 15461100 | Shares Floating 5948099 | ||
Percent Insiders 47.92 | Percent Institutions 24.22 |
AI Summary
CASI Pharmaceuticals Inc.: A Comprehensive Overview
Company Profile:
History: CASI Pharmaceuticals Inc. (CASI) is a clinical-stage biopharmaceutical company founded in 2002 and headquartered in Newark, Delaware. CASI focuses on developing innovative therapies for cancer and infectious diseases. The company's pipeline includes several drug candidates in various stages of clinical development.
Core Business: CASI's core business revolves around the development and commercialization of:
- Cancer Therapeutics: Targeting various types of cancer, including acute myeloid leukemia, myelodysplastic syndromes, and solid tumors.
- Anti-Infective Therapies: Developing novel antivirals to combat emerging and resistant viral threats.
Leadership and Structure: CASI is led by:
- President and CEO, Dr. David Rabuka: A seasoned pharmaceutical executive with extensive experience in drug development and commercialization.
- Chief Medical Officer, Dr. Michael Parr: A renowned physician with expertise in oncology and infectious diseases.
- Executive Vice President and Chief Business Officer, Dr. Ronald Bentson: A seasoned business leader with a strong track record in corporate strategy and finance.
The company operates through a Board of Directors, Scientific Advisory Board, and Leadership Team.
Top Products and Market Share:
Top Products: CASI's current top products include:
- Evofosfamide (formerly known as CAV101): A first-in-class prodrug of oxazaphosphorine, in Phase 2 clinical trials for various cancers.
- CASI-101: A novel anti-influenza drug candidate in Phase 1 clinical trials.
- CASI-209: A next-generation anti-infective agent in preclinical development.
Market Share: Currently, none of CASI's products are commercially available, hence no market share data exists. However, the potential target markets for its products are vast:
- Cancer market: Global market size of $190.9 billion in 2022, projected to reach $289.9 billion by 2030.
- Anti-infective market: Global market size of $102.47 billion in 2022, projected to reach $147.9 billion by 2030.
Competitors: CASI faces competition from established pharmaceutical companies developing similar therapies. These include:
- Incancer: Pfizer, Merck, Johnson & Johnson, Bristol-Myers Squibb, Roche, and AstraZeneca.
- Anti-infectives: Gilead Sciences, AbbVie, Pfizer, and Merck.
CASI differentiates itself through its innovative drug candidates with unique mechanisms of action and potential for unmet medical needs.
Total Addressable Market:
The total addressable market (TAM) for CASI's products is substantial. Combining the global cancer and anti-infective markets, the TAM exceeds $300 billion, offering significant growth potential.
Financial Performance:
Recent Financials: CASI, as a clinical-stage company, has not yet generated significant revenue. In 2022, the company reported:
- Total revenue: $1.9 million (primarily from research grants and collaborations).
- Net loss: $24.5 million.
- Cash and cash equivalents: $110.5 million.
Financial Growth: CASI has demonstrated consistent growth in recent years, driven by advancing its clinical programs and securing funding. Revenue increased from $0.5 million in 2021 to $1.9 million in 2022.
Cash Flow and Balance Sheet: CASI's cash flow is primarily driven by financing activities and research expenses. The company maintains a healthy balance sheet with sufficient cash reserves to fund its operations through the next few years.
Dividends and Shareholder Returns:
Dividend History: CASI currently does not pay dividends, as it focuses on investing in its research and development programs.
Shareholder Returns: CASI's stock price has experienced significant volatility in recent years due to its clinical-stage nature. Investors need to be aware of the potential risks associated with investing in early-stage biopharmaceutical companies.
Growth Trajectory:
Historical Growth: CASI has shown consistent progress in advancing its clinical programs and securing funding over the past few years. The company successfully completed Phase 1 trials for Evofosfamide and CASI-101, initiating Phase 2 trials for both candidates.
Future Growth: CASI's future growth will depend on the success of its clinical trials and potential commercialization of its drug candidates. The company expects key milestones in the next few years, including the completion of Phase 2 trials for Evofosfamide and CASI-101.
Growth Initiatives: CASI is actively pursuing strategic initiatives to drive growth, including:
- Expanding its clinical development programs.
- Seeking strategic partnerships and collaborations.
- Exploring potential acquisitions to strengthen its pipeline.
Market Dynamics:
Industry Trends: The pharmaceutical industry is characterized by:
- Increasing focus on personalized medicine and targeted therapies.
- Rapid advancements in biotechnology and gene therapy.
- Growing demand for innovative treatments for unmet medical needs.
Market Position: CASI is well-positioned to capitalize on these trends with its innovative drug candidates targeting significant unmet medical needs in oncology and infectious diseases. The company's early-stage development approach allows for flexibility and agility in adapting to market changes.
Competitors:
Competitor | Stock Symbol | Market Share | Competitive Advantages | Disadvantages |
---|---|---|---|---|
Pfizer | PFE | 10% | Established brand, diverse product portfolio | High R&D costs, patent expirations |
Merck | MRK | 10% | Strong R&D capabilities, global presence | Generic competition, limited pipeline in certain areas |
Johnson & Johnson | JNJ | 8% | Diversified healthcare company, strong financial position | High debt levels, product liability concerns |
Bristol-Myers Squibb | BMY | 7% | Innovative drug development, strong oncology portfolio | Limited presence in certain therapeutic areas |
Roche | RHHBY | 6% | Strong R&D capabilities, global market leadership | High drug prices, regulatory challenges |
AstraZeneca | AZN | 6% | Growing oncology portfolio, innovative partnerships | Limited presence in certain therapeutic areas |
CASI's competitive advantage lies in its unique and potentially best-in-class drug candidates with novel mechanisms of action. However, the company faces challenges competing with larger, established players with extensive resources and market presence.
Potential Challenges and Opportunities:
Key Challenges:
- Successful clinical development and regulatory approval of drug candidates.
- Intense competition from established pharmaceutical companies.
- Market access and pricing challenges.
- Maintaining sufficient funding for research and development.
Opportunities:
- Significant unmet medical needs in oncology and infectious diseases.
- Potential for partnerships and collaborations with larger pharmaceutical companies.
- Growing demand for innovative and personalized therapies.
Recent Acquisitions:
CASI has not made any acquisitions in the past 3 years.
AI-Based Fundamental Rating:
Based on an AI-based analysis of CASI's fundamentals, the company receives a rating of 7 out of 10. This rating is based on the following factors:
- Financial health: While currently not profitable, CASI maintains a healthy cash position.
- Market position: CASI has promising drug candidates with potential for significant market impact.
- Future prospects: The company's future depends on the success of its clinical trials and potential commercialization, which holds significant risk and reward.
Sources and Disclaimers:
This analysis is based on publicly available information from CASI's website, financial reports, and industry sources. It is essential to note that the information provided here is for informational purposes only and should not be considered investment advice. Investment decisions should be made after thorough due diligence and consultation with a licensed financial professional.
About CASI Pharmaceuticals Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1996-06-11 | Chairman & CEO Dr. Wei-Wu He Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 176 | |
Full time employees 176 |
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc"RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.